CD274 and neoplasm: Neoadjuvant camrelizumab plus chemotherapy is being investigated in patients with LACC (IB3 to IIB/IIIC1, PD-L1 positive, with a tumor diameter ≥4 cm) in the NACI study (NCT04516616), a single-arm, phase II clinical trial.